1110 - AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Kevin M. Tuffy, MS

Senior Scientist
AstraZeneca
Gaithersburg, Maryland, United States

MA

Michael E. Abram, PhD

AstraZeneca
Gaithersburg, Maryland, United States
TR

Tiffany L. Roe, B.S.

AstraZeneca
Gaithersburg, Maryland, United States
BA

Bahar Ahani, BSC

AstraZeneca
Gaithersburg, Maryland, United States
TB

Tyler Brady, MS

AstraZeneca
Gaithersburg, Maryland, United States
NS

Nicolette Schuko, MS

AstraZeneca
Gaithersburg, Maryland, United States
LC

Lori Clarke, B.S.

AstraZeneca
Gaithersburg, Maryland, United States
CC

Carolina Caceres, MS

AstraZeneca
Gaithersburg, Maryland, United States
TK

Tara Kenny, MS

AstraZeneca
Gaithersburg, Maryland, United States
VT

Virginia Takahashi, B.S.

AstraZeneca
Gaithersburg, Maryland, United States
TZ

Tianhui Zhang, PhD

AstraZeneca
Gaithersburg, Maryland, United States
DT

David E. Tabor, PhD

AstraZeneca
Gaithersburg, Maryland, United States
Gustavo H. Kijak, PharmD PhD (he/him/his)

Principal Scientist
AstraZeneca
Gaithersburg, Maryland, United States
EK

Elizabeth J. Kelly, PhD

AstraZeneca
Gaithersburg, Maryland, United States
KS

Katie Streicher, PhD

AstraZeneca
Gaithersburg, Maryland, United States